Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Snyder EL, Wheeler AP, Refaai M, Cohn CS, Poisson J, Fontaine M, et al. Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion. 2022;62(7):1365-1376.

Ramkissoon SH, Fernandes H, Lopez-Terrada DH, Hameed MR, Trembath DG, Bridge JA, et al. Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors. Arch Pathol Lab Med. 2022.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.

Man L, Guahmich NL, Kallinos E, Caiazza B, Khan M, Liu Z-, et al. Chronic superphysiologic AMH promotes premature luteinization of antral follicles in human ovarian xenografts. Sci Adv. 2022;8(10):eabi7315.

Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, et al. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2022;21(10):103158.

Karamchandani DM, Westerhoff M, Arnold CA, Gonzalez RS, Westbrook LM, Goetz L, et al. Interobserver Variability in Assessment of Depth of Submucosal Invasion for Colonic Endoscopic Resections Among Subspecialized Gastrointestinal Pathologists. Arch Pathol Lab Med. 2022;147(5):534-545.

Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, et al. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022;40(35):4119-4128.

Panarelli NC. In Reply. Arch Pathol Lab Med. 2022;146(10):1182a-1182.

Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, et al. A multidisciplinary approach to optimize primary prostate cancer biobanking. Urol Oncol. 2022;40(6):271.e1-271.e7.

Cayrol F, Revuelta MV, Debernardi M, Paulazo A, Phillip JM, Zamponi N, et al. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2022;21(9):1485-1496.